Effects of chronic therapy with cardiac contractility modulation electrical signals on cytoskeletal proteins and matrix metalloproteinases in dogs with heart failure

Cardiology

Volumn 110, Issue 4, 2008, Pages 230-237

  Rastogi, Sharad ^a   Mishra, Sudhish ^a   Zacà, Valerio ^a   Mika, Yuval ^b   Rousso, Benny ^b   Sabbah, Hani N ^a,c  

^a HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^b IMPULSE Dynamics   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

Cardiac contractility modulation; Cytoskeletal proteins; Heart failure; Titin

Indexed keywords

CONNECTIN; CYTOSKELETON PROTEIN; FIBRONECTIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL EMBOLISM; CONTROLLED STUDY; DOG; GENE EXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MUSCLE; HEART MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; CARDIAC PACING, ARTIFICIAL; CYTOSKELETAL PROTEINS; DOGS; ELECTROPHYSIOLOGY; HEART FAILURE; MATRIX METALLOPROTEINASES; MYOCARDIAL CONTRACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 46349099925     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112405     Document Type: Article

References (33)

1. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000;283:1295-1302.
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
3. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
4. Packer M: Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope. J Am Coll Cardiol 1988;12:1299-1317.
5. The PROMISE Study Group: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
6. Auricchio A, Stellbrink C, Block M, Sack S, Vogt J, Bakker P, Klein H, Kramer A, Ding J, Salo R, Tockman B, Pochet T, Spinelli J: Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. Circulation 1999;99:2993-3001.
7. Kass DA, Chen CH, Curry C, Talbot M, Berger R, Fetics B, Nevo E: Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. Circulation 1999;99:1567-1573.
8. Morita H, Suzuki G, Haddad W, Mika Y, Tanhehco EJ, Goldstein S, Ben-Haim S, Sabbah HN: Long-term effects of non-excitatory cardiac contractility modulation electric signals on the progression of heart failure in dogs. Eur J Heart Fail 2004;6:145-150.
9. Lawo T, Borggrefe M, Butter C, Hindricks G, Schmidinger H, Mika Y, Burkhoff D, Pappone C, Sabbah HN: Electrical signals applied during the absolute refractory period: an investigational treatment for advanced heart failure in patients with normal QRS duration. J Am Coll Cardiol 2005;46:2229-2236.
10. Pappone C, Augello G, Rosanio S, Vicedomini G, Santinelli V, Romano M, Agricola E, Maggi F, Buchmayr G, Moretti G, Mika Y, Ben-Haim SA, Wolzt M, Stix G, Schmidinger H: First human chronic experience with cardiac contractility modulation by nonexcitatory electrical currents for treating systolic heart failure. J Cardiovasc Electrophysiol 2004;15:418-427.
11. Wu Y, Bell SP, Trombitas K, Witt CC, Labeit S, LeWinter MM, Granzier H: Changes in titin isoform expression in pacing-induced cardiac failure give rise to increased passive muscle stiffness. Circulation 2002;106:1384-1389.
12. Imai M, Rastogi S, Gupta RC, Mishra S, Sharov VG, Stanley W, Mika Y, Rousso B, Burkhoff D, Ben-Haim S, Sabbah HN: Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J Am Coll Cardiol 2007;49:2120-2128.
13. Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S, Hawkins ET, Goldstein S: A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol 1991;260:H1379-H1384.
14. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, Goldstein S: Effects of long-term monotherapy with enalapril, metoprolol and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-2859.
15. Stix G, Borggrefe M, Wolpert C, Hindricks G, Kottkamp H, Bocker D, Wichter T, Mika Y, Ben-Haim S, Burkhoff D, Wolzt M, Schmidinger H: Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failure. Eur Heart J 2004;25:650-655.
16. Keller TCS: Structure and function of titin and nebulin. Curr Opin Cell Biol 1995;7:32-38.
17. Wu Y, Cazorla O, Labeit D, Labeit S, Granzier H: Changes in titin and collagen underlie diastolic stiffness diversity of cardiac muscle. J Mol Cell Cardiol 2000;32:2151-2162.
18. Cazorla O, Freiburg A, Helmes M, Centner T, McNabb M, Wu Y: Differential expression of cardiac titin isoforms and modulation of cellular stiffness. Circ Res 2000;86:59-67.
19. Warren CM, Jordan MC, Roos KP, Krzesinski PR, Greaser ML: Titin isoform expression in normal and hypertensive myocardium. Cardiovasc Res 2003;59:86-94.
20. Neagoe C, Kulke M, del Monte F, Gwathmey JK, de Tombe PP, Hajjar RJ, Linke WA: Titin isoform switch in ischemic human heart disease. Circulation 2002;106:1333-1341.
21. Aquila-Pastir LA, Dipaola NR, Matteo RG, Smedira NG, McCarthy PM, Moravec CS: Quantification and distribution of β-tubulin in human cardiac myocytes. J Mol Cell Cardiol 2002;34:1513-1523.
22. Sharov VG, Kostin S, Todor A, Schaper J, Sabbah HN: Expression of cytoskeletal, linkage and extracellular proteins in failing dog myocardium. Heart Fail Rev 2005;10:297-303.
23. Heling A, Zimmermann R, Kostin S, Maeno Y, Hein S, Devaux B, Bauer E, Klovekorn WP, Schlepper M, Schaper W, Schaper J: Increased expression of cytoskeletal linkage and extracellular proteins in failing human myocardium. Circ Res 2000;86:846-853.
24. Kossmehl P, Schonberger J, Shakibaei M, Faramarzi S, Kurth E, Habighorst B, von Bauer R, Wehland M, Kreutz R, Infanger M, Schulze-Tanzil G, Paul M, Grimm D: Increase of fibronectin and osteopontin in porcine hearts following ischemia reperfusion. J Mol Med 2005;83:626-637.
25. Tagawa H, Wang N, Narishige T, Ingber DE, Zile MR, Cooper G: Cytoskeletal mechanics in pressure-overload cardiac hypertrophy. Circ Res 1997;80:281-289.
26. Hein S, Kostin S, Heling A, Maeno Y, Schaper J: The role of the cytoskeleton in heart failure. Cardiovasc Res 2000;45:273-278.
27. Lemler MS, Bies RD, Frid MG, Sastravaha A, Zisman LS, Bohlmeyer T, Gerdes AM, Reeves JT, Stenmark KR: Myocyte cytoskeletal disorganization and right heart failure in hypoxia-induced neonatal pulmonary hypertension. Am J Physiol 2000;279:H1365-H1376.
28. Thomas CV, Coker MI, Zellner JL, Handy JR, Crumbley AJ, Spinale FG: Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998;97:1708-1715.
29. Rastogi S, Gupta RC, Mishra S, Morita H, Tanhehco EJ, Sabbah HN: Long-term therapy with acorn cardiac support device normalizes gene expression of growth factors and gelatinases in dogs with heart failure. J Heart Lung Transplant 2005;10:1619-1625.
30. Li YY, McTiernan CF, Feldman AM: Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000;40:214-224.
31. Lu L, Gunja-Smith Z, Woessner JF: Matrix metalloproteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo. Am J Physiol 2000;279:H601-H609.
32. Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L, Crawford J, Black S, Libby P, Mitchell PG, Lee RT: Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 2002;105:753-758.
33. Morita H, Khanal S, Rastogi S, Suzuki G, Imai M, Todor A, Sharov VG, Goldstein S, O'Neill TP, Sabbah HN: Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Am J Physiol 2006;290:H2522-H2527.